Non-Surgical Option Approved for Recurrent Low-Grade Bladder Cancer

Watchdoq June 12, 2025
(MedPage Today) -- The FDA approved mitomycin intravesical solution (Zusduri) as a nonsurgical option for recurrent low-grade, intermediate-risk non-muscle invasive bladder cancer (NMIBC).
The product won the indication despite a negative recommendation...

Read Full Article